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Matrix metalloproteinases (MMPs) are extracellular matrix–modifying enzymes that are important in many physiologic
and pathologic vascular processes. Dysregulation of MMP activity has been associated with common vascular diseases
such as atherosclerotic plaque formation, abdominal aortic aneurysms, and critical limb ischemia. For this reason, MMPs
have become an important focus for basic science studies and clinical investigations by vascular biology researchers. This
article reviews the recent literature, summarizing our current understanding of the role of MMPs in the pathogenesis of
various peripheral vascular disease states. In addition, the importance of MMPs in the future diagnosis and treatment of
peripheral vascular disease is discussed. (J Vasc Surg 2007;45:849-57.)THE PHYSIOLOGIC ROLE OF MATRIX
METALLOPROTEINASES
The cellular components of blood vessels are supported
and organized by a complex structure of collagens, elastins,
laminins, fibronectins, and proteoglycans known as the
extracellular matrix (ECM).1 Once believed to be merely a
simple, mechanical lattice between cells, the ECM is now
recognized to be a dynamic structure that facilitates and
even governs cellular activity.2 Researchers in nearly every
medical discipline are examining the ECM in their quest to
arrest disease, with many of the most promising advances
taking place in cardiovascular research.
Much of this cardiovascular research is focused on the
family of ECM-remodeling enzymes collectively termed
the matrix metalloproteinases (MMPs). Twenty-three
MMPs have been described in humans, and although they
share a high degree of homology in their structure, their
functions as ECM-modifiers vary tremendously (Table).
Most MMPs are secreted freely into the extracellular space
immediately after synthesis as proenzymes, but some are
stored within cells (eg, MMP-9 in neutrophil granules),
and others are bound to cell surface membranes (eg, MT1-
MMP).3,4
Rigorous regulation of MMP production and activity is a
crucial part of ECM homeostasis. This regulation takes place
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doi:10.1016/j.jvs.2006.09.066primarily at the levels of gene transcription, pro-MMP activa-
tion, and endogenous inhibition. MMPs are formed as inac-
tive proenzymes and are activated by proteolysis in the extra-
cellular fluid, a process that is tightly regulated by other
proteases and by endogenous MMP inhibitors.3,4
Plasma proteins (eg -2 macroglobulin) and tissue inhib-
itors of metalloproteinases (TIMPs) are the primary endoge-
nous inhibitors of MMPs, although they also serve other
physiologic functions. For example, TIMP-2 inhibits
MMP-2, but is also required for MT1-MMP–mediated acti-
vation of proMMP-2.5 The vascular microenvironment pro-
vides several specificmodes ofMMP regulation. For example,
the cyclic strain on endothelial cells created by arterial pulsa-
tion has been shown to increase expression and activity of
MMP-2 and its activator, MT1-MMP.6,7 Furthermore,
emerging evidence suggests that nitric oxide inhibits gene
expression of MMP-2 from endothelial cells,8 and MMP-9
from endothelial cells and vascular smooth muscle cells. 9
MMPs contribute to many normal and necessary physio-
logic processes through their modification of the ECM.10
These processes vary widely, ranging from embryonic devel-
opment, wound healing, and keratinocyte migration to the
initiation of menstruation.11-13 Inflammation accompanied
by increased MMP activity also contributes to many disease
processes as several MMPs are sequestered in inflammatory
cells. In fact, increased inflammation and loss of MMP regu-
lation is the hallmark of many pathologic states, including
many of the disease processes treated by vascular surgeons.
MATRIX METALLOPROTEINASES IN
PERIPHERAL VASCULAR DISEASE
Atherosclerosis. Atherosclerotic disease in the coro-
nary and peripheral arterial circulation is the leading cause
of morbidity and mortality in the United States.14 Athero-
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several distinct steps, many of which have been associated
with alterations in MMP activity.15 Specifically, MMP dys-
regulation is associated with leukocyte infiltration, vascular
smooth muscle cell (VSMC) migration, and intraplaque
matrix remodeling, each of which are key elements in
atherosclerotic plaque formation.16,17 The most intriguing
investigations, however, have studied the role of MMPs in
plaque instability and rupture.
Mature atherosclerotic plaques contain several sources of
MMPs, most notably VSMCs (ie, MMP-2) and macro-
phages/foam cells (ie, MMP-1, MMP-2, MMP-3, MMP-7,
and MMP-9).17 Loss of intraplaque MMP regulation pro-
vokes degradation of the matrix-rich fibrous cap of an
atherosclerotic lesion, leading to eventual plaque disrup-
tion. This occurs primarily at the plaque “shoulders” (Fig 1),
where mechanical stress caused by arterial pressure is the
Table. Major human matrix metalloproteinases and associ
MMP Associated vascular pathologies M
MMP-1 AAA, atherosclerosis Fibrillar collagen
MMP-2 AAA, atherosclerosis, arterial
restenosis, critical limb ischemia
Denatured collag
MMP-3 AAA, atherosclerosis, varicose veins Proteoglycan, pr
MMP-7 Atherosclerosis Proenzymes, fibr
MMP-8 AAA, atherosclerosis Fibrillar collagen
MMP-9 AAA, atherosclerosis, arterial
restenosis, critical limb ischemia
Denatured collag
MMP-10 Atherosclerosis Proteoglycan, pr
MMP-11 Atherosclerosis Proteoglycan, pr
MMP-12 AAA, atherosclerosis Elastin, fibronect
MMP-13 AAA, atherosclerosis Fibrillar collagen
MMP-14 AAA, atherosclerosis Collagens, proM
MMP, Matrix metalloproteinase; AAA, abdominal aortic aneurysm.
Fig 1. A, Matrix metalloproteinases (MMP), derived from
smooth muscle cells (SMCs) and macrophages, degrade the ath-
erosclerotic lesion at the “plaque shoulder” where mechanical
stress is highest. B, This eventually results in plaque ulceration and
disruption.highest.18MMP-9 is specifically associated with plaque instability
in the coronary circulation.19 An analysis of human coro-
nary atherectomy specimens has also demonstrated higher
levels of active intraplaque MMP-9 in patients with unsta-
ble angina (ie, unstable coronary plaques) compared with
patients with stable angina (ie, stable coronary plaques).20
In addition, elevated plasma MMP-9 levels in carotid end-
arterectomy patients are highly associated with histologic
markers of unstable plaque structure as well as acute neu-
rovascular events.21 These studies demonstrate an associa-
tion between MMP-9 and atherosclerotic plaque instabil-
ity, suggesting that MMP-9 may be crucial in acute arterial
insufficiency and complications caused by plaque rupture.
Clinical implications
Diagnosis. The link between plasma MMP-9 and
plaque instability has led to interest in using this biomarker
as a diagnostic tool, particularly in patients presenting with
unstable angina and myocardial infarction. Although sev-
eral studies have associated elevated plasma MMP-9 levels
with acute coronary syndromes, a more rigorous correla-
tion between MMP-9 levels and clinical status must be
determined before this test can have diagnostic value.22
Treatment. The 3-hydroxy-3 methyl-glutaryl-
coenzyme A reductase inhibitors (statins) reduce mortality
at a rate that exceeds predictions based solely on the cor-
rection of hypercholesterolemia. Statins have plaque-
stabilizing qualities that may be associated with an anti-
MMP effect.23 In vitro studies have shown that fluvastatin
inhibits macrophage secretion of MMP-9, the MMP cur-
rently most closely linked with plaque instability.23 Recent
studies have also demonstrated statin inhibition ofMMP-7,
another MMP that has been linked to atherosclerotic
plaque disruption.24,25 As the MMP-inhibitory qualities of
these very common medications are investigated further,
the beneficial effects of statins on atherosclerosis may prove
to be even more valuable and complex than previously
vascular pathologies
substrates Alternative names
onectin Collagenase-1, interstitial collagenase
bronectin, elastin Gelatinase A, 72kda gelatinase
genase, fibronectin Stromelysin-1
in, other matrix proteins Matrilysin
onectin, Collagenase-2, neutrophil collagenase
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For years, atherosclerotic arterial wall damage and hy-
pertension were believed to be the primary cause of abdom-
inal aortic aneurysms (AAAs). The current understanding,
however, characterizes AAA pathogenesis as a chronic pro-
cess of inflammation, degradation, and transformation
within the aortic wall, although the inducing factor remains
elusive.26
Histologic studies of aneurysmal aortas have demon-
strated specific changes in cellular content, including in-
flammatory cell infiltration and apoptosis of VSMCs.27,28
Characteristic changes within the ECM of the aortic wall
also occur, including a marked decrease in elastin content
and an increase in collagen synthesis.29 This decrease in the
elastin/collagen ratio weakens the aortic wall, reduces its
compliance, and leaves it susceptible to the mechanical
stress of arterial pressure.26 Proteolysis of elastin also results
in the release of elastin degradation product, which are
biologically active matrikines that have a role in chemotaxis
of inflammatory cells, release of MMP-1 and MMP-2, and
SMC proliferation.30 These processes contribute to AAA
development. In fact, application of an elastin degradation
product to rat aortas resulted in aortic expansion and
adventitial neovascularization in an experimental model.31
MMP-2 and MMP-9 are MMPs with significant elastin-
degrading activity.32 Accordingly, alterations in the activity
levels MMP-2 and MMP-9 as well as TIMP-1, the endog-
enous inhibitor of MMP-9, appear to have a role in AAA
pathogenesis.
Matrix metalloproteinase 2. MMP-2 is constitu-
tively expressed by VSMCs and is a key contributor to
normal aortic ECM homeostasis.26 Numerous human and
animal studies have demonstrated increased MMP-2 mes-
senger RNA (mRNA), total MMP-2 levels, and MMP-2
activity in aneurysmal aortas compared with normal and
atherosclerotic aortas.33,34 Furthermore, in contrast to
wild-type mice, MMP-2 knockout (KO) mice do not form
aneurysms in response to aortic injury.35 This evidence
suggests that MMP-2 contributes to AAA formation.
Matrix metalloproteinase 9. Unlike MMP-2, MMP-9
is found in negligible amounts in normal aortic tissue.
MMP-9 is sequestered in neutrophils, macrophages, and
other inflammatory cells. The presence of MMP-9 in aortic
tissue is associated with chronic inflammation and macro-
phage infiltration, processes that are characteristic of AAA
formation.36 In fact, investigations have shown a correla-
tion between elevated aortic tissueMMP-9 levels and AAAs
in both humans and animal models.37 Plasma MMP-9
levels are also elevated in patients with AAAs compared
with controls.38 Finally, MMP-9 KO mice are resistant to
aneurysm formation in response to aortic injury.39 Of interest
is that these MMP-9 KO mice lose their resistance to
aneurysm formation after transplantation of wild-type bone
marrow capable of producing MMP-9–competent macro-
phages.39 These results support the hypothesis that inflam-
matory cell presentation of MMP-9 is important for aneu-
rysm formation.In addition to its association with the initial formation
of AAAs, MMP-9 has also been implicated in promoting
the rupture of large, otherwise stable AAAs. Petersen et al40
demonstrated that levels of MMP-9 were increased in
ruptured aneurysms compared with intact large aneu-
rysms.40 These data suggest that MMP-9 –mediated degra-
dation of the aortic ECM may have a crucial role in the
rupture of AAAs.
Tissue inhibitor of metalloproteinase 1. As the pri-
mary endogenous inhibitor of MMP-9, TIMP-1 may have
a protective effect on AAA formation.26 This is suggested
by the fact that TIMP-1 KO mice form larger aneurysms
after elastase infusion than wild-type mice.41 Furthermore,
Allaire et al42 have demonstrated that overexpression of
TIMP-1 prevents both elastin depletion and aneurysm
formation and rupture in a rat model of AAA.42 Additional
studies are needed to further define the role of TIMP-1 in
AAA pathogenesis.
Clinical implications
Diagnosis. The use of plasma MMP-9 levels as a
screening biomarker for undiagnosed AAA has been at-
tempted; unfortunately, normal MMP-9 levels lack the
negative predictive value necessary to be used in this man-
ner.38 Nevertheless, plasma MMP-9 levels may be useful
for monitoring patients after endovascular AAA repair
(EVAR). Plasma MMP-9 levels rise sharply after open
repair, most likely due to aneurysm sac manipulation, and
remain elevated for 3 months. Patients undergoing
EVAR do not demonstrate this transient elevation in
plasma MMP-9 levels. Instead, the MMP-9 levels decrease
gradually to well below preoperative values by 1 month
after surgery if the aneurysm sac is excluded from the
circulation.43 In the presence of an endoleak, however,
blood continues to circulate through the aneurysm sac, and
plasma MMP-9 levels remain increased. Given the expense
and risk of serial computed tomography scanning, it is
plausible that serial measurement of plasma MMP levels
will prove useful in the future for postoperative monitoring
for endoleaks after EVAR.43,44
Treatment. The link between MMPs and AAAs has
generated hope for a potential medical therapy. Some
investigators believe that AAAs will eventually be treated
primarily with medication in well-cared-for popula-
tions.45,46 Several synthetic, broad-spectrum MMP inhib-
itors (eg, batimistat, marimistat) have been developed for
in vivo use, although their utility in the treatment of AAA
has not yet been determined.
Of interest is that doxycycline, a well known, cheap and
relatively innocuous antibiotic, has generated considerable
excitement as a potential treatment for AAA as well as other
conditions mediated by MMPs (eg, periodontitis and ar-
thritis). Doxycycline binds the zinc-containing active site of
MMPs, nonselectively inhibiting MMP activity. It also acts
to diminish cellular MMP expression.47 Clinical trials dem-
onstrate decreased plasma MMP-9 levels as a result of
long-term administration of doxycycline.48 Rat and mouse
models exhibit inhibition of aneurysm formation after sys-
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cal trial in Finland of 32 patients with small AAAs demon-
strated reduced aneurysm expansion at 12 and 18 months
in patients treated with doxycycline compared with
placebo.50 Finally, recent evidence suggests that local de-
livery of doxycycline, directly targeting the aorta without
systemic administration, also reduces aortic expansion in a
mouse model of AAA.51 Local delivery of doxycycline
could be accomplished in humans by using drug-eluting
stent grafts, thus reducing systemic complications of doxy-
cycline and eliminating the noncompliance associated with
oral therapy. Further studies may demonstrate that doxy-
cycline indeed has utility as a medical treatment for AAA.
In addition to doxycycline, several other medical ther-
apies may prove useful for the treatment of AAA via inhi-
bition of MMP activity. As already mentioned, statins have
MMP-inhibitory properties.23,25 A recent study using a
mouse model of AAA showed that the administration of
simvastatin reduced expression of aortic wall MMP-9, in-
creased expression of TIMP-1, and reduced aortic expan-
sion.52 Not surprisingly, clinical studies show that statins
reduce the rate of AAA growth during 12 and 24months of
follow-up in two series of patients.53,54 Rapamycin, which
has been shown to decrease aortic expansion and MMP-9
levels in a rat model of AAA, is another potential anti-MMP
therapy that may be useful in reducing AAA expansion.55
Finally, recent evidence indicates that inhibition of c-Jun
N-terminal kinase (JNK), a proximal signaling molecule
crucial for MMP-2 and MMP-9 secretion, prevents the
development of AAA and even caused regression of existing
AAAs in mouse models. These findings may translate into
medical therapies that could utilize MMPs as a therapeutic
target in the treatment of AAA.56
CRITICAL LIMB ISCHEMIA
After occlusion of a major artery, ischemic limbs revas-
cularize via the distinct mechanisms of arteriogenesis and
angiogenesis.57 Arteriogenesis is the dilatation of pre-existing
collateral vessels in response to changes in intravascular
shear stress.58 Angiogenesis is the de novo development of
vessels from existing capillaries in response to tissue isch-
emia.59 These transformations in the macrovasculature and
microvasculature require changes in both the cellular and
extracellular components of blood vessels and their sur-
rounding tissues. Accordingly, investigations into the
mechanisms of MMP-mediated ECM remodeling during
revascularization are underway. Although limited evidence
currently exists concerning the role ofMMPs in arteriogen-
esis, significant evidence links MMP activity to the process
of angiogenesis.
MMP-2 and MMP-9 have both been associated with
angiogenesis. Many animal studies investigating angiogen-
esis in critical limb ischemia use the mouse hind limb
ischemia model in which unilateral femoral artery ligation is
performed.60 The study limb of a wild-type mouse is ini-
tially profoundly ischemic after this surgery. Over the
course of 28 days, however, the limb partially revascular-
izes, with perfusion reaching 50% to 80% of the nonisch-emic control limb, depending on the strain of mouse.60
Associated with this spontaneous revascularization is a
marked elevation in tissue levels of active and total MMP-2
and MMP-9 within the ischemic limb muscle.61 In addi-
tion, MMP-9 KO mice exhibit delayed and incomplete
revascularization compared to wild-type mice.62 This indi-
cates that MMP-9 has a specific role in the angiogenic
process that can not be compensated for by MMP-2, even
though both enzymes have similar substrates.
Human data on MMP activity in critical limb ischemia
is limited. However, a study published in 2005 demon-
strated a linear correlation between plasma MMP-9 levels
and the severity of ischemia in patients with varying degrees
of peripheral arterial occlusive disease (PAOD).63
MMPs such as MMP-2 and MMP-9 may have a role in
promoting angiogenesis that goes far beyond simply de-
grading the ECM to allow vessels to “burrow through” and
develop. In fact, ECM remodeling results in changes that
contribute to the regulation of angiogenesis. MMPs release
matrix-bound growth factors such as vascular endothelial
growth factor (VEGF) that influence endothelial cell mi-
gration and proliferation.64
Interesting current evidence suggests that the ECM
contains hidden signaling sites within basement membrane
and interstitial matrix collagen. Monoclonal antibodies
identify cryptic collagen regulatory sites HUIV26 and
HU177.65 MMP-9 – dependent exposure of HUIV26 has
been shown to be necessary for angiogenesis in several
models.66,67 Furthermore, studies using the mouse hind
limb ischemia model demonstrate that the cryptic collagen
site HU177 is exposed within ischemic muscle in a tempo-
ral fashion paralleling MMP-2 and MMP-9 activity.61,62
This relationship between the ECM and surrounding cells
is leading to further investigations designed to elucidate the
role of MMPs in angiogenesis in critically ischemic limbs.
Critical limb ischemia associated with diabetes
mellitus. Patients with diabetes mellitus and PAODhave a
fivefold increase in the rate of amputation caused by critical
limb ischemia than do patients without diabetes.68 Diabe-
tes mellitus alters the expression and function of MMPs,
which may accelerate the progression of PAOD in affected
patients. In vitro studies using a high glucose medium have
demonstrated increased endothelial cell–derived MMP-1
and MMP-2 expression and activity as well as increased
expression and activity of MMP-9 from monocytes.69 Fur-
thermore, these changes in MMP expression and activity
may result in altered revascularization in response to critical
limb ischemia in diabetic patients.
Indeed, a study using a hind limb ischemia model in
diabetic and wild-type mice demonstrated diminished re-
vascularization and angiogenesis in diabetic animals that
was associated with increased expression of MMP-2 and
markedly increased expression of MMP-12.70 A more com-
plete understanding of MMP function in diabetic patients
will provide insight in to the complex milieu of physiologic
derangements associated with diabetic vascular disease.
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Successful endoluminal treatment of atherosclerotic le-
sions is limited by postintervention restenosis. Restenosis is
the result of arterial remodeling that occurs by two distinct
and complementary processes: intimal hyperplasia and con-
strictive remodeling.71 ECM remodeling by MMPs is in-
volved in each of these processes.
Intimal hyperplasia. Intimal hyperplasia is a thicken-
ing of the tunica intima resulting in narrowing of the vessel
lumen. It occurs in several normal physiologic states, most
notably during closure of the ductus arteriosus after birth72
and is also a major cause of pathologic arterial restenosis
after angioplasty and stenting procedures. The hallmark of
intimal hyperplasia is VSMC migration into the intima,
which reduces the luminal diameter. Degradation of the
basement membrane portion of the ECM is essential for
this VSMCmigration, and the role of MMPs in this process
is actively being expolored.71,72
Elevated tissue levels ofMMP-2 andMMP-9 have been
identified in pig models of vein bypass grafts, temporally
coinciding with the period of SMCmigration and neointimal
formation.73 Rats given batimastat, a generalized MMP in-
hibitor, demonstrated reduced neointimal formation com-
pared with controls after Fogarty balloon–denuding injury of
the common carotid artery.74 In a separate study using a
similar rat model, the nonselective MMP-inhibitor doxycy-
cline decreased intimal hyperplasia and reduced MMP-2
and MMP-9 activity in arterial wall specimens.75 Mice
deficient for TIMP-1, the endogenous MMP-9 inhibitor,
also demonstrated significantly increased neointimal for-
mation compared with wild-type mice after periadventitial
electric femoral artery injury.76
Specific MMP KO mice have been studied to more
clearly define the role of individual MMPs in intimal hyper-
plasia. MMP-9 KO mice demonstrated decreased intimal
hyperplasia, decreased luminal loss, and decreased VSMC
migration in a carotid artery flow-cessation model of arte-
rial remodeling.77 A separate study using a carotid artery–
denuding injury model in MMP-9 KO mice demonstrated
decreased VSMC replication, VSMC migration, and arte-
rial lesion formation compared with wild-type mice, further
suggesting a role for MMP-9 in intimal hyperplasia.78
MMP-2 KOmice also exhibit decreased intimal hyperplasia
and decreased VSMC migration in a carotid artery flow-
cessation model.79 Further studies involving genetically
modified mice or the development of selective in-vivo
MMP inhibitors should help to elucidate further the roles
of specific MMPs in intimal hyperplasia.
Constrictive remodeling. Geometric arterial remod-
eling results in a change in total arterial diameter, causing
concentric dilatation or constriction of the lumen and
arterial wall. Expansive arterial remodeling, also called
compensatory enlargement or positive remodeling, is a
concentric increase in luminal and total arterial diameter
and was first reported by Glagov et al in 1987. This group
described compensatory dilatation of coronary arteries inresponse to partial occlusion of the lumen by atheroscle-
rotic plaque. This expansive remodeling is a protective
compensatory mechanism that preserves luminal cross-
sectional area despite significant plaque burden.80
In contrast, constrictive remodeling is a concentric
decrease in luminal and total arterial diameter. Constrictive
remodeling occurs in response to angioplasty and is a major
cause of postintervention restenosis, distinct from intimal
hyperplasia (Fig 2).71 Constrictive remodeling is believed
to be the result of changes in collagen and elastin metabo-
lism mediated by alterations in MMP activity after angio-
plasty.81 Angioplasty is a specific form of tissue injury, and
the blood vessel wall responds accordingly by demonstrat-
ing features of wound healing such as deposition of colla-
gen and tissue contraction. These changes, which are partly
mediated by MMPs, result in arterial constriction and loss
Fig 2. After angioplasty, arterial luminal narrowing occurs by the
distinct processes of constrictive remodeling and intimal hyperpla-
sia. Intimal hyperplasia is a localized process, resulting in smooth
muscle cell migration into the intima and luminal narrowing. In
contrast, constrictive remodeling is a diffuse, transmural process
resulting in concentric reduction of the luminal and total arterial
diameter. Matrix metalloproteinase (MMP) activity contributes to
both of these pathologic processes.of luminal and arterial diameter.17
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plasty constrictive remodeling after the administration of
MMP inhibitors. De Smet et al82 reported that batimastat
significantly decreased constrictive remodeling and late lu-
men loss after balloon angioplasty in pigs.82 A second study
using the oral MMP inhibitor marimastat in a similar pig
model yielded similar results.83 These studies suggest that
MMP activity may be integral to constrictive remodeling
and loss of vessel diameter after endoluminal therapy.
Therapeutic potential. Because studies in rodents
and pigs suggest that postangioplasty intimal hyperplasia
and constrictive remodeling may be decreased through
MMP inhibition, similar studies have been attempted in
higher animals and in humans. In one study, atherosclerotic
monkeys were given the broad-spectrum MMP inhibitor
RO113-2908 after iliac artery stenting. Of interest was that
no difference in lumen diameter, intimal hyperplasia, or
constrictive remodeling was identified between the study
and control groups after 4 weeks.84 Two separate human
studies using drug-eluting stents containing batimastat
have also been performed. The results of these human
studies showed neither angiographic improvement nor a
decreased requirement for endoluminal reintervention as a
result of MMP inhibition.85,86 It is unclear if these disap-
pointing findings are the result of limitations in drug deliv-
ery, incomplete MMP inhibitory activity of the drugs, or if
these studies simply demonstrate the ineffectiveness of
MMP inhibition in reducing restenosis. Because the results
of these primate and human studies contradict the data
obtained from lower animal studies, further investigations
are clearly necessary to determine if MMP inhibition has a
role in the treatment of arterial restenosis by intimal hyper-
plasia and constrictive remodeling.
VENOUS DISEASE
Varicose veins. More than a century has passed since
Trendelenberg’s 1891 proposal implicating valvular in-
competence in the pathogenesis of varicose vein disease.
Although this model is still being taught today, the current
understanding of ECM remodeling in vascular disease has
sparked interest in new theories of varicose vein pathogen-
esis.87 Varicose vein development may, in fact, be mech-
anistically similar to AAA development. Decreased vessel
wall strength, alterations in ECM content, and MMP dys-
regulation may play a key role.88
Interstitial collagen III is important for the stretch
resistance of the connective tissue of veins. MMP-3 may
contribute to vein wall weakness and varicose vein forma-
tion via excessive degradation of collagen III. Kowalewski
et al88 have demonstrated that MMP-3 levels in varicose
vein biopsy specimens are almost twice as high as those found
in healthy veins.
An in vitro study by Sansilvestri-Morel et al89 supports
this finding. They showed that VSMCs cultured from var-
icose veins produce higher levels of MMP-3 than VSMCs
from healthy veins. This study also demonstrated a reduc-
tion of collagen III in the culture media of varicose vein
VSMCs. Despite this reduction in collagen III, levels ofcollagen III propeptide are comparable with levels found in
the control VSMC cultures, indicating that collagen III is
produced in both cultures in similar amounts. This finding
suggests that the decreased collagen III levels in the vari-
cose vein cultures are due to extracellular degradation,
likely owing to increased MMP-3 activity rather than de-
creased production.89 This evidence suggests a role for
MMP-3 in varicose vein pathogenesis and is the basis for
continuing investigations.
Deep vein thrombosis. Deep vein thrombosis (DVT)
is a significant clinical problem that can result in devastating
acute events such as pulmonary embolism. Post-thrombotic
syndrome occurs in a significant percentage of patients after
DVT resolution and results in pain, edema, and ulceration,
yet the pathogenesis of this syndrome is unclear.90 Several
investigators propose a mechanism by which inflammation
and MMP hyperactivity associated with thrombus resolu-
tion result in vein wall injury, scarring, and post-thrombotic
sequelae.91-93
Increased MMP-9 expression is associated with the
early phase of DVT resolution.91 Recent studies by Henke
et al92 in neutropenic rats suggest that this early increase in
MMP-9 is associated with neutrophil infiltration within the
thrombus; moreover, increased MMP-2 transcription and
activity in the vein wall is associated with the late phase of
DVT resolution in experimental models.91,93 In addition,
increased levels of MT1-MMP, a membrane-bound activa-
tor of MMP-2, are associated with this increased MMP-2
expression and activity, further suggesting a role for
MMP-2 in DVT pathophysiology.93 Continued elucida-
tion of the role of MMPs in DVT resolution and post-
thrombotic vein wall changes may demonstrate that MMPs
are a potential therapeutic target in preventing the long
term sequelae of DVT.
Chronic venous ulcers. Successful wound repair re-
quires a tightly coordinated proteolytic response involving
multiple MMPs, including MMP-1, MMP-2, MMP-7,
MMP-9, and MMP-10.11,12 In contrast, loss of MMP
regulation may be significant in the pathogenesis of
chronic, nonhealing wounds such as venous ulcers.94 Sev-
eral studies have demonstrated increased MMP-2 expression
and activity in chronic venous ulcers.95-97 Furthermore, in-
creased expression of the MMP-2 activator MT1-MMP is
also found in chronic venous ulcers, further suggesting a
role for MMP-2 in this disease process.97
The specific role of MMP2 in venous ulcer pathogen-
esis remains unclear, however. MMP-2 hyperactivity may
inhibit wound healing via excessive basement membrane
degradation leading to loss of epidermal integrity.95
In vitro studies have demonstrated diminished angiogene-
sis in the presence of exudate taken from chronic venous
ulcers. This decreased angiogenesis was reversed by the
addition of an inhibitor of MMP-2 and MMP-9, suggest-
ing that the MMP balance in chronic venous ulcers has an
antiangiogenic effect.98 In a bench-to-bedside effort, a
recent trial examined the potential therapeutic benefit of
MMP-inhibitor-impregnated dressing for the treatment
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ity may prove useful in the treatment of venous ulcers.
CONCLUSION
MMPs continue to represent an exciting focus for basic
science and clinical investigation in peripheral vascular dis-
ease. Many traditional theories of vascular pathophysiology
have already been set aside in favor of newly discovered,
MMP-mediated mechanisms. A new class of therapeutic
agents may soon be developed that will offer patients
noninvasive methods for treating vascular disease. The in-
troduction of endovascular technology has transformed the
way vascular disease is treated. It is possible that therapeutic
modulation of MMP function may one day change the
practice of vascular surgery even further.
We thank Elizabeth Gagne, PhD, for her critique of
this manuscript, as well as Kenneth Axen, PhD, for his
artistic skill in designing and drawing the figures.
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